XTRA:MDG1Biotechs
The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business
The subdued stock price reaction suggests that Medigene AG's ( ETR:MDG1 ) strong earnings didn't offer any surprises...
XTRA:MDG1Biotechs
Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%
One thing we could say about the analysts on Medigene AG ( ETR:MDG1 ) - they aren't optimistic, having just made a...
XTRA:VSCABiotechs
We Think 4SC (ETR:VSCA) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
XTRA:HPHABiotechs
Private equity firms are Heidelberg Pharma AG's (ETR:HPHA) biggest owners and were rewarded after market cap rose by €20m last week
Every investor in Heidelberg Pharma AG ( ETR:HPHA ) should be aware of the most powerful shareholder groups. We can see...
XTRA:FYBBiotechs
Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)
Shareholders in Formycon AG ( ETR:FYB ) may be thrilled to learn that the analysts have just delivered a major upgrade...
XTRA:MORBiotechs
Amidst increasing losses, Investors bid up MorphoSys (ETR:MOR) 13% this past week
MorphoSys AG ( ETR:MOR ) shareholders should be happy to see the share price up 13% in the last week. But only the...
XTRA:MDG1Biotechs
Loss-Making Medigene AG (ETR:MDG1) Set To Breakeven
With the business potentially at an important milestone, we thought we'd take a closer look at Medigene AG's ( ETR:MDG1...
XTRA:CNWBiotechs
Breakeven On The Horizon For co.don AG (ETR:CNW)
We feel now is a pretty good time to analyse co.don AG's ( ETR:CNW ) business as it appears the company may be on the...
XTRA:FYBBiotechs
Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...